The Novacor left ventricular assist system: clinical experience from the Novacor registry

Area of Science:

• Cardiovascular Surgery
• Biomedical Engineering
• Medical Devices

Background:

• The Novacor left ventricular assist system (LVAS) has been clinically utilized since 1984.
• Evolution to a wearable model in 1993 and conduit modification in 1998 improved device safety and efficacy.
• Over 1100 implants globally represent extensive clinical experience.

Purpose of the Study:

• To evaluate the safety and long-term efficacy of the Novacor LVAS.
• To assess the device's performance across different clinical applications: bridge to transplant, bridge to recovery, and permanent support.
• To analyze device reliability and patient outcomes based on cumulative data.

Main Methods:

• Review of clinical data from over 1100 Novacor LVAS implants worldwide.
• Analysis of device evolution, including modifications to the inflow conduit.
• Assessment of cumulative patient support duration and device replacement rates.

Main Results:

• The Novacor LVAS has demonstrated a low replacement rate of only 0.7%.
• A 1998 modification to the inflow conduit resulted in a 50% reduction in embolic events.
• Cumulative patient support exceeds 300 patient-years, with documented long-term support up to 4 years.

Conclusions:

• The Novacor LVAS is a safe and effective option for patients with advanced heart failure.
• The device provides reliable long-term mechanical circulatory support.
• Its versatility supports various treatment strategies, including bridge to transplant, recovery, or permanent implantation.